Tirzepatide with Control-IQ to reduce meal announcements
What this study tests
McGill-led phase 2/3 trial testing whether weekly tirzepatide can help adults using Tandem Control-IQ reduce or eliminate carbohydrate counting and meal announcements while preserving daytime time-in-range.
Editorial review: .
Registry checked: 2026-09-17. Registry’s own update: 2026-05-27.
Most recent recorded citation date: 2026-05-27. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence at a glance
- Who can enter the study?
- Adults with type 1 diabetes. Registered eligibility ↗Enrollment criteria describe who may enter. They do not establish who was analyzed or the denominator for a reported result.
- Reported benefit and results
- No results posted yet.Read the result sources and their limitations →
- Important harms
- Read the reported results, safety discussion and original sources. A separate harms summary is not available; this does not establish safety.
- Research access and approval
- Study regions: Canada, Other regions. A trial listing does not establish product approval or current recruitment at a particular site. Check the study’s current entry requirements.
- What remains uncertain?
- Read the full discussion and original sources for study limitations. Planned endpoints and completion dates are not results.
Research status alone does not establish approval, clinical benefit or local availability.
Primary endpoints
- Daytime time-in-range during the final 6 weeks of the study
The full picture
This record has no longer discussion. Use the study criteria, reported results and original sources on this page to assess what is known and what remains unresolved.
Sources
- [1]A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar · Trial registry · 2026-05-27 — RECRUITING; estimated n=105; actual start 19 May 2026; primary completion January 2028 and study completion January 2029.